UnitedHealth to Acquire Amedisys for $101/Share
By Dean Seal
UnitedHealth Group has agreed to acquire Amedisys for $101 a share.
The healthcare-services provider said in a securities filing on Monday it has agreed to a merger with UnitedHealth in which each Amedisys share will be converted into the right to $101 in cash.
Amedisys will become a wholly owned subsidiary of UnitedHealth.
The Baton Rouge, La.-based company said earlier this month that it had received an unsolicited proposal from a unit of UnitedHealth for a takeover at $100 a share.
The new bid disrupted Amedisys' previously announced plans to combine with Option Care in an all-stock deal.
Amedisys shares ticked up by less than 1% to $91.74 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 26, 2023 09:09 ET (13:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track